OTC Markets OTCQB - Delayed Quote USD

LadRx Corporation (LADX)

1.7000

+1.7000

(0.00%)

As of January 24 at 3:00:00 PM EST. Market Open.

LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates

LOS ANGELES, December 12, 2024--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company is restarting a process to seek marketing approval of aldoxorubicin under the provisions of the FDA’s Section 505(b)(2).

Business Wire last month

LADX
0.00%
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

LOS ANGELES, June 03, 2024--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. ("NantCell"), together with NantCell’s parent company ImmunityBio, Inc. ("ImmunityBio"), have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017.

Business Wire 7 months ago

LADX
0.00%

Performance Overview

Return	LADX	S&P 500
YTD	+2.41%	+1.74%
1-Year	+13.33%	+22.88%
3-Year	+240.00%	+38.16%